CNSP
CNS Pharmaceuticals, Inc.
There isn't enough reported data to score CNSP yet.
CNSP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
CNSP's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
CNSP PE Valuation
CNSP has no meaningful PE right now: it lost money over the past year.
CNSP Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect CNSP's losses to shrink, with revenue holding steady.
CNSP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$470,413.44 | -$164,816.64 |
| Q2 2023 | -$519,013.44 | -$168,416.64 |
| Q1 2023 | -$568,813.44 | -$164,216.64 |
| Q4 2022 | -$553,710.24 | -$76,710.24 |
| Q3 2022 | -$305,596.80 | +$252,403.20 |
| Q2 2022 | -$350,596.80 | +$189,403.20 |
| Q1 2022 | -$404,596.80 | +$135,403.20 |
| Q4 2021 | -$477,000.00 | +$36,000.00 |
CNSP lost $35.43 per share over the past year, a smaller loss than the year before.
CNSP Quarterly Revenue
CNSP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.5M | +$1.8M |
| Q1 2026 | -$4.7M | -$1.4M |
| Q4 2025 | -$3.1M | +$2.4M |
| Q2 2025 | -$5.3M | -$3.7M |
| Q1 2025 | -$3.2M | -$49.9K |
| Q4 2024 | -$5.5M | -$2.9M |
| Q1 2024 | -$3.2M | +$1.6M |
| Q4 2023 | -$2.5M | -$233.2K |
CNSP has burned cash in almost every quarter: −$13M over the past year, against −$16M the year before.
CNSP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +911% | +6.2M shares |
| 1 year | +2910% | +6.6M shares |
| 3 years | +15541275% | +6.8M shares |
| 5 years | +37989928% | +6.8M shares |
CNSP has 7M diluted shares, up 2910% from a year ago.
CNSP Net Leverage
CNSP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CNSP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.5 | Neutral |
| Stochastic | 20.9 | Neutral |
CNSP's weekly RSI is 34 (neutral) and its Stochastic is 21 (neutral).
CNSP PE vs Healthcare Sector
CNSP has no meaningful PE right now: it lost money over the past year.
CNSP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.75 | 24% below |
| 20 week MA | $5.16 | 30% below |
| 50 week MA | $4.76 | 24% below |
| 100 week MA | $13.7 | 74% below |
| 200 week MA | $14,716.6 | 100% below |
CNSP is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
CNSP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3,519,000.0 | $1,602,000.0 | -54% |
| 2021 | $1,602,000.0 | $780,570.0 | -51% |
| 2022 | $780,570.0 | $65,700.0 | -92% |
| 2023 | $65,700.0 | $38,100.0 | -42% |
| 2024 | $38,100.0 | $67.8 | -100% |
| 2025 | $67.8 | $6.17 | -91% |
| 2026 YTD | $6.17 | $3.62 | -41% |
CNSP has finished every year since 2020 lower, and it's down 41% so far in 2026.